BASF recently announced the launch of Accelon™ absorption accelerating technology, developed as a breakthrough solution to the bioavailability challenge of today’s omega-3 supplements. Results from clinical studies showing significantly increased absorption with Accelon™ will be presented at the GOED Exchange 2018, which is taking place in Seattle, United States, from February 6-8.
Accelon™ delivers a minimum of four times better absorption of omega-3 in comparison to other market-leading high concentrate omega-3 products. This results in a higher delivery of EPA and DHA to cells throughout the body. Accelon™ therefore represents a highly distinct and relevant innovation for the omega-3 supplements category, setting new standards for absorption.
“The bioavailability topic is particularly important because poorly absorbed products, sometimes compounded by low potency, are likely to have limited benefits,” says Øyvind Ihle, Head of Global Omega-3 Nutrition at BASF. “Consumers taking their supplements in good faith risk not enjoying the full range of benefits they are hoping and paying for.”
Accelon™ will enable the global omega-3 industry to attract new users, build positive perceptions and give consumers genuine reasons to believe omega-3 is beneficial to their daily lives.
Exploring Comparative Omega-3 Bioavailability of Different Chemical Forms
BASF is a Platinum Sponsor at GOED Exchange 2018, where the “Clarifying the Controversies in the Omega-3 Industry” session will explore the comparative bioavailability of different chemical forms as well as bioavailability improvements from new technologies, concluding with a look at the world of bioavailability marketing and claims.
Keynote Speaker Philip Calder, Professor of Nutritional Immunology in the Faculty of Medicine at the University of Southampton, U.K., will place the spotlight on omega-3 absorption, highlighting recent trials using BASF’s Accelon™ absorption accelerating technology. This presentation will take a close look at the fate of EPA and DHA after intake and absorption. The fatty acid composition, in particular that of EPA and DHA, in different tissues will be described, as well as details on how EPA and DHA distribute into different chemical forms within tissues. Calder will also summarize strategies for enhancing EPA and DHA levels and discuss how acute and chronic studies compare.
Kevin Maki, PhD, Founder and Chief Science Officer of the Midwest Centre for Metabolic & Cardiovascular Research, will discuss biological sources and forms for long chain omega-3 fatty acids as supplements, drugs and in food, showing the differences in absorption between drug/supplement formulations and factors that influence absorption enhancement of Omega-3 fatty acids.
The session will be completed by Adam Ismail, GOED Executive Director, who explores the use of ‘bioavailability’ as an omega-3 marketing theme, the accuracy of product claims and some of the regulatory and ethical challenges associated with them.